Healthcare analysts have cautioned investors against blind optimism for long-term gains after the ASX surged on Tuesday morning on positive news about a possible coronavirus vaccine.
Local medtechs across the board have been pivoting their research to coronavirus treatments and cures, with some seeing big share price gains. Stem cell companyDespite this, analysts warn investors that there are hurdles in the way for companies hoping to achieve share price gains from treatment research.
Ms Quinn ceased coverage of Mesoblast earlier this year but observed that while the company had taken its first steps into research, "they don’t yet have a track record of launching a product". "My sense is that there’s quite an onus on these companies to take a humanitarian as opposed to commercial point of view," she said.
MsEmmaK The only information you can believe is anything depressing and negative. They will always be truthful. But Always be cautious on anything positive.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: smh - 🏆 6. / 80 続きを読む »